Molecular analysis of single cells provides an important basis for precision medicine. Five years ago, scientists around the world came together to pursue the “Human Cell Atlas” project, with the aim of cataloging all cells in the human body. These data have helped, for example, to identify those cell types that the coronavirus can infect particularly well. To accelerate and improve the creation of such cell catalogs, Paul Datlinger and André F. Rendeiro from Christoph Bock’s research group at CeMM developed a new method that enables single-cell RNA sequencing in a very large number of individual cells at the same time.
This method, which is called “scifi-RNA-seq” (for: “single-cell combinatorial fluidic indexing”), marks the RNA of many cells with specific barcodes, before the cells are loaded on a microfluidic chip and their RNA is prepared for single-cell sequencing. These additional barcodes overcome an important problem with existing methods for single-cell sequencing, where single cells are packed into tiny emulsion droplets and assigned cell-specific barcodes. When several cells land in the same droplet, they receive the same barcode and can no longer be distinguished. Therefore, the single cell suspension is loaded onto the microfluidic chip at low concentrations, which means that most of the emulsion droplets remain empty, and the reagents are used very inefficiently.
In the scifi-RNA-seq method, the cells are marked in advance with an additional barcode. As a result, the emulsion droplets can be loaded with many cells at the same time, while it is still possible to analyze individual cells. Study author Paul Datlinger explains: “On the popular 10x Genomics system, we use this method to measure 15 times more individual cells. The additional barcode also allows the user to mark and combine thousands of samples in advance, and to process those samples together in a single microfluidic analysis. As part of our study, we performed a CRISPR screen with single-cell RNA sequencing readout in human T cells. In the future, our method may, among other things, help to improve immunotherapies for the treatment of cancer.”
An efficient high-throughput method with a wide range of applications
Projects that need to apply single-cell RNA sequencing to very large numbers of cells or very many samples will particularly benefit from the new method. Project leader Christoph Bock explains: “scifi-RNA-seq enables efficient RNA sequencing for millions of individual cells, which facilitates the characterization of complex tissues, organs, and entire organisms. Moreover, in biomedicine it is often useful to analyze many single cells, for example to discover rare stem cells in tumors or cancer cells in the blood. Finally, scifiRNA-seq will contribute to the trend that drug screens and CRISPR screens are increasingly combined with high-resolution single-cell sequencing readouts. “
The study “Ultra-high-throughput single-cell RNA sequencing and perturbation screening with combinatorial fluidic indexing” was published in Nature Methods on 31 Mai 2021 (online ahead of print), DOI: 10.1038/s41592-021-01153-z
Authors: Paul Datlinger, André F. Rendeiro, Thorina Boenke, Martin Senekowitsch, Thomas Krausgruber, Daniele Barreca, Christoph Bock
Funding: This work was conducted in the context of two Austrian Science Fund (FWF) Special Research Program grants (FWF SFB F6102; FWF SFB F7001). Thomas Krausgruber was supported by a Lise Meitner fellowship from the Austrian Science Fund (FWF M2403). Christoph Bock is supported by an ERC Starting Grant (European Union’s Horizon 2020 research and innovation program, grant agreement no. 679146).
Christoph Bock is a principal investigator at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences in Vienna, where he has led a research group since 2012, and a professor of medical informatics at the Medical University of Vienna since 2021. Before Christoph Bock joined CeMM, he was a postdoc at the Broad Institute of MIT and Harvard and at Harvard University (2008-2011), and a PhD student at the Max Planck Institute for Informatics (2004-2008). He is also scientific coordinator of the Biomedical Sequencing Facility of CeMM and MedUni Vienna, “key researcher” at the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases (LBI-RUD), fellow of the European Lab for Learning and Intelligent Systems (ELLIS), and elected member of the Young Academy of the Austrian Academy of Sciences. He has received important research awards, including the Otto Hahn Medal of the Max Planck Society (2009), an ERC Starting Grant (2016-2021), an ERC Consolidator Grant (2021-2026), and the Overton Prize of the International Society for Computational Biology (2017). For 2019 and 2020 he was included in the global list of “Highly Cited Researchers” by Clarivate Analytics (ISI Web of Science).
The mission of CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences is to achieve maximum scientific innovation in molecular medicine to improve healthcare. At CeMM, an international and creative team of scientists and medical doctors pursues free-minded basic life science research in a large and vibrant hospital environment of outstanding medical tradition and practice. CeMM’s research is based on post-genomic technologies and focuses on societally important diseases, such as immune disorders and infections, cancer and metabolic disorders. CeMM operates in a unique mode of super-cooperation, connecting biology with medicine, experiments with computation, discovery with translation, and science with society and the arts. The goal of CeMM is to pioneer the science that nurtures the precise, personalized, predictive and preventive medicine of the future. CeMM trains a modern blend of biomedical scientists and is located at the campus of the General Hospital and the Medical University of Vienna. www.cemm.at
Medical University of Vienna (MedUni Vienna) is one of the most traditional medical education and research facilities in Europe. With almost 8,000 students, it is currently the largest medical training center in the German-speaking countries. With 5,500 employees, 30 departments and two clinical institutes, 12 medical theory centers and numerous highly specialized laboratories, it is also one of Europe's leading research establishments in the biomedical sector. www.meduniwien.ac.at/web/en